Evidence map›Paper›PMID 39291303›Full record

Trial reportAllergy2025

HLA-DR

Xiaoying Zhou, Diane Dunham, Sayantani B Sindher, Andrew Long, Andrea Fernandes, Iris Chang, Amal Assa'ad, Jacqueline Pongracic, Jonathan M Spergel, Jonathan Tam and 5 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02626611 (A Phase 2 Study Multi Oral Immunotherapy in Multi Food Allergic Patients to Test Tolerance M-TAX Study), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02626611 phase2completednot on this map

A Phase 2 Study Multi Oral Immunotherapy in Multi Food Allergic Patients to Test Tolerance M-TAX Study

TypeinterventionalSponsorKari Christine NadeauRan2015 to 2016Enrolled70ConditionsFood AllergyArmsOmalizumab, Food Flour Buildup
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Diverging in Vivo Immune Response Patterns After Oral Food Challenge in Peanut Allergic Adults.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Article
  2. Review
  3. The Expanding Role of Omalizumab: From Food Allergy to Drug Desensitization.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiaoying ZhouDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-3177-3271
Diane DunhamDepartment of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.ORCID https://orcid.org/0009-0003-0884-1285
Sayantani B SindherDepartment of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.ORCID https://orcid.org/0000-0003-0387-2800
Andrew LongDepartment of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.ORCID https://orcid.org/0000-0001-8198-5937
Andrea FernandesDepartment of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.ORCID https://orcid.org/0000-0002-2855-4262
Iris ChangDepartment of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.ORCID https://orcid.org/0009-0007-1971-8513
Amal Assa'adDivision of Allergy and Immunology, Cincinnati Children's Medical Center, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0001-7791-6859
Jacqueline PongracicDivision of Allergy and Immunology, The Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0003-4084-6994
Jonathan M SpergelDivision of Allergy and Immunology, Department of Pediatrics, The Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-4658-5353
Jonathan TamDivision of Clinical Immunology and Allergy, Children's Hospital Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-5769-227X
Stephen TillesSeattle Allergy and Asthma Research Institute, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-1291-7479
Julie WangDivision of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID https://orcid.org/0000-0002-8113-9092
Scott D BoydDepartment of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.ORCID https://orcid.org/0000-0003-0963-044X
R Sharon ChinthrajahDepartment of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.ORCID https://orcid.org/0000-0003-2467-4256
Kari C NadeauDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-2146-2955

Funding

Effects of IgE Blockade on T Cells in Food AllergyR01AI140134 · NIAID · STANFORD UNIVERSITY · PI NADEAU, KARI C. · 2018 to 2021
$1.6M
Bezos FoundationHartman Family FoundationNIAID NIH HHS R01 AI140134NIH HHSSunshine foundationthe Sean N. Parker Center for Allergy and Asthma Research at Stanford University
6 · The paper itself

Abstract

backgroundOmalizumab (XOLAIR®)-assisted multi-food oral immunotherapy (mOIT) has been shown to safely, effectively, and rapidly desensitize patients with multiple food allergies. In our clinical trial (NCT02626611) on omalizumab-assisted mOIT, different desensitization outcomes (success or failure of desensitization) were observed following a period of either continued or discontinued mOIT. However, the association between the immunological changes induced by omalizumab-assisted mOIT and desensitization outcomes has not yet been fully elucidated. In this study, due to the key roles of regulatory T (Treg) cells and the type 2 helper T cell (Th2) pathway in immune tolerance to food allergens, we aimed to characterize their association with the desensitization outcomes of omalizumab-assisted mOIT.

methodsMass cytometry and multiplex cytokine assays were performed on blood samples obtained from participants with allergies to peanut, cashew, or milk in our phase 2 clinical study (NCT02626611). Comprehensive statistical and bioinformatic analyses were conducted on high-dimensional cytometry-based single-cell data and high-throughput multiplex cytokine data.

resultsOur results demonstrated that the frequency of HLA-DR

conclusionsWe demonstrated that the frequency of HLA-DR

Indexed as

Desensitization, ImmunologicFood HypersensitivityHLA-DR AntigensInterleukin-10T-Lymphocytes, RegulatoryAdultAllergensCytokinesFemaleHumansMaleMiddle AgedOmalizumabTreatment OutcomeAllergensCytokinesHLA-DR AntigensInterleukin-10Omalizumabbasic immunologybiologicsclinical immunologyfood allergyimmune toleranceimmunotherapy and tolerance inductionT cells

Identifiers

PMID39291303
PMCPMC11893263

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.